Vistagen Secures FDA “Study May Proceed” Clearance for Refisolone IND, Advancing Phase 2 Development in Menopause-Related Vasomotor Symptoms Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company focused on advancing neuroscience through its proprietary nose-to-brain neurocircuitry platform, has announced a key…
PureTech Reports Positive Phase 1b Topline Data for LYT-200 in Relapsed/Refractory High-Risk MDS and AML PureTech Health plc, a hub-and-spoke biotherapeutics company focused on transforming scientific innovation into value and advancing novel therapies across a range of serious diseases, has…
FDA Grants Approval to Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir) Merck & Co. (NYSE: MRK), known as MSD outside the United States and Canada, has announced that the U.S. Food and Drug Administration has approved IDVYNSO, a novel once-daily, two-drug single-tablet regimen…
Genentech’s Enspryng (Satralizumab) Cuts Relapse Risk by 68%, Showing Promise as a Potential First Treatment for MOGAD Genentech, a member of the Roche Group, has announced compelling new results from its Phase III METEOROID clinical trial evaluating Enspryng (satralizumab) in…
n-Lorem Foundation Reaches Key Milestone with 50th Nano-Rare Patient Treated Using a Personalized Antisense Oligonucleotide Therapy n-Lorem, a nonprofit foundation dedicated to advancing precision genetic medicine for individuals with ultra-rare conditions, has reached a significant milestone with the treatment of…
Annals of Internal Medicine Reports One-Year Findings from LivaNova’s OSPREY Clinical Trial in Obstructive Sleep Apnea LivaNova PLC (Nasdaq: LIVN) has announced the publication of comprehensive 12-month results from its landmark OSPREY randomized controlled trial (RCT) in the prestigious Annals…
Neurogene Announces Christy Shafer as Chief Commercial Officer and Appoints Christine Mikail, J.D., to Its Board Neurogene Inc. has announced key leadership additions as it advances its mission to develop transformative therapies for rare neurological diseases. The company has appointed…
Bicycle Therapeutics Shares Pipeline Update on Nuzefatide Pevedotin and EphA2 Programs at AACR 2026 Bicycle Therapeutics has unveiled a comprehensive set of updates from its EphA2-targeting oncology pipeline at the American Association for Cancer Research Annual Meeting, highlighting growing clinical…
Zai Lab shares preclinical data showing ZL-1503 delivers rapid itch relief and reduces inflammation in atopic diseases Zai Lab Limited has announced promising new preclinical findings for ZL-1503, its internally developed IL-13/IL-31Rα bispecific antibody, highlighting the therapy’s potential to address…
Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™ Drug Farm has announced promising early clinical and immunologic data from its ongoing Phase 1b study evaluating DF-003, a first-in-class oral inhibitor…
LEO Pharma expands its psoriasis portfolio in China with NMPA approval of Enstilar® LEO Pharma A/S has announced a significant regulatory milestone with the approval of Enstilar by China’s National Medical Products Administration (NMPA) for the treatment of adult patients…
WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug–Device Combination Product Development and Manufacturing WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has successfully achieved ISO 13485:2016 Medical Device Quality…